Re-inventing the wheel: the use of autologous and fresh donor blood in cardiac surgery

Abstract

From the opening of a new cardiac surgical programme in November 1992, autologous and fresh donor blood (FDB) were used rather than cold stored blood (CSB) wherever possible in patients undergoing operations involving the use of cardiopulmonary bypass (CPB).

In the first 250 consecutive patients, autologous blood was used in 168 (67.2%), fresh blood was used in 188 (75.2%). A total of 740 units of fresh blood were obtained on the day of operation (mean 3.9 ± 1.6 units per patient able to supply donors; 4.9 ± 1.7 units in the 147 who received fresh blood) and 728 units of stored blood were used (mean 3.08 ± 1.84 units per patient where fresh blood was used; 6.2 ± 2.5 units in the 114 where no fresh blood was used).

The use of autologous blood significantly reduced FDB and CSB requirements (p < 0.001), was associated with a shorter intensive care and total postoperative stay (p = 0.006 and p = 0.033 respectively), even though there were more urgent and emergency cases in this group (p = 0.009) and no significant difference in chest drainage.

Coagulopathy developed in 41 patients (16.4%) and was significantly associated with bypass time (p = 0.0001) and preoperative renal dysfunction (p = 0.005), although not with advanced age, sex, redo operation, diabetes or glucose-6-phosphate dehydrogenase deficiency. Patients with coagulopathy had significantly more transfused blood and blood products (p = 0.0001) and longer intensive care and total postoperative stays (p = 0.0001).

In terms of blood conservation, the use of autologous blood was of primary importance. Correction of renal dysfunction and keeping overall bypass time to a minimum reduced the incidence of coagulopathy and, therefore, blood use. The use of FDB in this series was not clearly associated with improved overall results, but did generate more blood than was actually used, a factor of extreme importance in situations where stored blood is always in short supply.

Get full access to this article

View all access options for this article.

References

Murphy PJ , Connery C. , Hicks GL Jr , Blumberg N. Homologus blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1992; 104: 1092-99.

Ottino G. , DePaulis R. , Pansini S. et al. Major sternal wound infection after open-heart surgery: a multivariate analysis of risk factors in 2,579 consecutive operative procedures. Ann Thorac Surg 1987; 44: 173-79.

Scott WJ , Rode R. , Castlemain B. et al. Efficacy, complications and cost of a comprehensive blood conservation programme for cardiac operations. J Thorac Cardiovasc Surg 1992; 103: 1001-1007.

Johnson RG , Thurer RL , Kruskall MS et al. Comparison of two transfusion strategies after elective operations for myocardial revascularisation. J Thorac Cardiovasc Surg 1992; 104: 307-14.

Gratz I. , Koehler J. , Olsen D. et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations . J Thorac Cardiovasc Surg 1992; 104: 1417-22.

Blauhut B. , Gross C. , Necek S. et al. Effects of high dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-67.

Havel M. , Teufelsbauer H. , Knobl P. et al. Effect of introperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:968-72.

DelRossi AJ , Cernaianu AC , Vertrees RA et al. Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 100: 281-86.